Augustine Therapeutics Expands Team with New Appointments
Augustine Therapeutics, a pioneering biotechnology company, has recently made significant strides by appointing Rie Schultz Hansen, PhD, as its new Chief Scientific Officer. This appointment is a vital part of Augustine's strategy to advance its innovative lead HDAC6 inhibitor program, AGT-100216, aimed at treating Charcot-Marie-Tooth Disease. The company is not only focusing on this significant development but is also building a robust pipeline targeting neurodegenerative and cardio-metabolic diseases.
Establishment of Copenhagen Subsidiary
In conjunction with the executive appointment, Augustine Therapeutics announced the inauguration of its subsidiary, Augustine Therapeutics Denmark ApS, located in Copenhagen. This new facility is designed to serve as the central hub for the company’s research efforts in cardio-metabolic medicine, highlighting Augustine's commitment to expanding its reach in this important area of healthcare.
The Expertise of Rie Schultz Hansen, PhD
Dr. Rie Schultz Hansen brings over two decades of experience in drug discovery and early-stage development. Her extensive background, particularly in cardio-metabolic and inflammation-based diseases as well as peptide therapeutics, makes her an asset to Augustine’s leadership team. Before joining Augustine, Dr. Hansen held the Chief Scientific Officer role at Aelin Therapeutics, where she was pivotal in creating a platform for targeted drug development through innovative methodologies.
Dr. Hansen's career at Zealand Pharma, a respected name in peptide development, encompassed various high-level roles including Vice President and Head of Discovery and Innovation, focusing on cutting-edge research in cardiovascular and metabolic diseases. Her profound insights into the biological mechanisms underlying these conditions will be indispensable as Augustine Therapeutics moves forward with its clinical aspirations.
Leadership Insights and Future Directions
Gerhard Koenig, PhD, the CEO of Augustine Therapeutics, expressed enthusiasm about bolstering the company’s executive team. He stated that Dr. Hansen’s diverse expertise will be crucial in progressing the company’s main product candidate, AGT-100216, through initial clinical trials for CMT, while supporting ongoing programs targeting additional conditions linked to neurodegenerative and cardio-metabolic disorders.
Transformative Impact on Cardio-Metabolic Research
As Dr. Hansen approaches her new role, she acknowledges the significant potential of Augustine's unique approach to selectively inhibit HDAC6. With the recent completion of a successful funding round that will enable further advancements in their research, she is optimistic about leading efforts to tap into the wealth of cardio-metabolic research capabilities concentrated in Denmark.
Dr. Hansen’s academic credentials are equally impressive; she earned both her Master's and PhD from the University of Copenhagen, specializing in biological sciences. Additionally, she serves on several influential committees including the Danish Cardiovascular Academy Grant committee, underscoring her commitment to advancing scientific research.
About Augustine Therapeutics
Founded on the innovative research led by Prof. Ludo Van Den Bosch from VIB-KU Leuven, Augustine Therapeutics is dedicated to tackling the challenges posed by neuromuscular, neurodegenerative, and cardio-metabolic diseases. The company is renowned for developing HDAC6 inhibitors that are designed to maintain the essential functions of HDAC6 while effectively addressing chronic disease conditions. Augustine’s flagship compound, AGT-100216, is the first specifically designed selective HDAC6 inhibitor targeting Charcot-Marie-Tooth disease, with aspirations to broaden its scope to other serious health conditions.
The company has successfully secured substantial investment, including an oversubscribed Series A funding round, which will further enable their ambitious research and development initiatives. As Augustine Therapeutics continues to grow, they remain focused on making meaningful contributions to the fields of neuromuscular and metabolic health.
Frequently Asked Questions
What role has Dr. Rie Hansen taken on at Augustine Therapeutics?
Dr. Rie Schultz Hansen has been appointed as Chief Scientific Officer at Augustine Therapeutics.
What is the main focus of Augustine Therapeutics?
Augustine Therapeutics focuses on developing therapies for neuromuscular, neurodegenerative, and cardio-metabolic diseases through innovative drug development.
Where is the new subsidiary for Augustine Therapeutics located?
The new subsidiary, Augustine Therapeutics Denmark ApS, is located in Copenhagen, Denmark.
What is AGT-100216?
AGT-100216 is Augustine Therapeutics' lead HDAC6 inhibitor program designed for treating Charcot-Marie-Tooth Disease.
How has Augustine Therapeutics been funded?
Augustine Therapeutics has successfully raised significant funding through an oversubscribed Series A funding round led by notable investors, including Novo Holdings.
